



ST.JUDE-viva Survivorship
SERIES 3

Webinar #5:

EXPECTED AND POTENTIAL LATE EFFECTS IN NEUROBLASTOMA SURVIVORS

15th Mar 2024 | 8:00PM – 9:30PM (GST +8 | Singapore Time)

Program Name:	St. Jude-VIVA Survivorship Series 3 Webinar #5
Event Date:	Friday, 15th March 2024
Event Time:	8:00pm – 9:30pm (Singapore Time)

Programme Synopsis

Lecture Title:

Expected and Potential Late Effects in Neuroblastoma Survivors

Dr Maggie Cupit-Link, St Jude. Children's Research Hospital, USA

Neuroblastoma is the most common extracranial solid tumor of childhood and is responsible for ~15% of childhood cancer deaths. It is a heterogenous disease with 5-year-survival rates of > 95% in children with low-risk disease, > 90% in those with intermediate-risk disease, and ~50% in those with high-risk disease. Thus, the treatment of neuroblastoma ranges from observation or surgery alone to an intensive multimodal approach including autologous stem cell transplantation and anti-GD2 immunotherapy.

In this lecture, expected late effects based on treatment exposures will be reviewed for each risk category. Additionally, modern era high-risk neuroblastoma therapy and its associated late effects will be discussed in detail, highlighting recently published data and ongoing studies. Finally, recommended surveillance and management of late effects will be reviewed.



Presenter Bio

Dr Maggie Cupit-Link

**St. Jude Children's Research Hospital
USA**

Maggie attended medical school at Mayo Clinic School of Medicine and completed a pediatric residency at St. Louis Children's Hospital/WashU. She is currently a 3rd year pediatric hematology/oncology fellow at St. Jude Children's Research Hospital and is earning a master's degree in clinical investigations through the St. Jude Graduate School.

As a clinician, she is committed to providing excellent and compassionate care to children with cancer, with a particular interest in solid tumors. As a clinical researcher, she is passionate about reducing both acute and long-term toxicities of cancer therapies in children—through both retrospective studies and prospective clinical trials. Her previous research/publications have addressed high-risk neuroblastoma treatment and its associated late effects, chemotherapy-induced nausea and vomiting, toxicities of modern immunotherapies, and quality of life in childhood cancer survivors.



Organising Chair/Moderator

Dr Melissa Hudson

**Member, St. Jude Faculty
Director, Cancer Survivorship Division
Co-Leader, Cancer Control & Survivorship Program
The Charles E. Williams Endowed Chair of Oncology-Cancer
Survivorship
St. Jude Children's Research Hospital
USA**